Cyclacel Pharmaceuticals Inc (CYCC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cyclacel Pharmaceuticals Inc (CYCC) has a cash flow conversion efficiency ratio of -0.291x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.06K) by net assets ($3.63K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cyclacel Pharmaceuticals Inc (CYCC) balance sheet quality index to measure how much of total assets are equity-financed.
Cyclacel Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Cyclacel Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CYCC operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Cyclacel Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclacel Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spirent Communications plc
LSE:SPT
|
0.039x |
|
Managepay Systems Bhd
KLSE:0156
|
-0.040x |
|
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
|
-0.084x |
|
Dome Gold Mines Ltd
AU:DME
|
-0.023x |
|
GENENTA SCIENCE(SP.ADR)/1
F:K5F
|
N/A |
|
Shah Alloys Limited
NSE:SHAHALLOYS
|
-0.149x |
|
ViroGates A/S
CO:VIRO
|
-0.879x |
|
Talius Group Ltd.
AU:TAL
|
-0.424x |
Annual Cash Flow Conversion Efficiency for Cyclacel Pharmaceuticals Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Cyclacel Pharmaceuticals Inc from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see Cyclacel Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.17 Million | $-7.99 Million | 3.675x | +113.85% |
| 2023-12-31 | $607.00K | $-16.11 Million | -26.544x | -2504.15% |
| 2022-12-31 | $20.43 Million | $-20.83 Million | -1.019x | -107.23% |
| 2021-12-31 | $37.69 Million | $-18.54 Million | -0.492x | -106.19% |
| 2020-12-31 | $33.26 Million | $-7.93 Million | -0.239x | +70.46% |
| 2019-12-31 | $11.70 Million | $-9.45 Million | -0.808x | -84.07% |
| 2018-12-31 | $15.27 Million | $-6.70 Million | -0.439x | -27.68% |
| 2017-12-31 | $21.77 Million | $-7.48 Million | -0.344x | +51.33% |
| 2016-12-31 | $14.27 Million | $-10.08 Million | -0.706x | +8.02% |
| 2015-12-31 | $18.84 Million | $-14.46 Million | -0.768x | +10.97% |
| 2014-12-31 | $21.69 Million | $-18.70 Million | -0.862x | -32.78% |
| 2013-12-31 | $28.02 Million | $-18.20 Million | -0.649x | +45.97% |
| 2012-12-31 | $10.02 Million | $-12.04 Million | -1.202x | -67.70% |
| 2011-12-31 | $19.50 Million | $-13.98 Million | -0.717x | -11.35% |
| 2010-12-31 | $24.92 Million | $-16.04 Million | -0.644x | +80.32% |
| 2009-12-31 | $4.64 Million | $-15.19 Million | -3.272x | -125.82% |
| 2008-12-31 | $20.64 Million | $-29.91 Million | -1.449x | -262.93% |
| 2007-12-31 | $57.97 Million | $-23.14 Million | -0.399x | -6.70% |
| 2006-12-31 | $53.92 Million | $-20.17 Million | -0.374x | +74.60% |
| 2005-12-31 | $14.60 Million | $-21.51 Million | -1.473x | -208.20% |
| 2004-12-31 | $44.12 Million | $-21.09 Million | -0.478x | -300.11% |
| 2003-12-31 | $-64.84 Million | $-15.49 Million | 0.239x | -- |
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more